Top Investments For 2014

The following video is from Monday's installment of Where the Money Is, in which Fool analysts Matt Koppenheffer and David Hanson highlight for investors the most important stock news from the financial sector.

In this segment, Matt discusses an article from The Wall Street Journal, which addressed the conflicting motivations between banking regulators and the big banks. As the spread between the interest rate at which banks can borrow money and the interest rate they are able to get for lending, or the net interest margin, continues to compress, many banks have been reducing the amount of long-term debt they have been carrying, as that often has a higher interest rate. Matt tells investors what it would mean for the big banks if regulations are imposed that require a higher amount of long-term debt to be maintained on these banks' balance sheets in preparation for the next banking crisis.

Bank of America's stock doubled in 2012. Is there more yet to come? With significant challenges still ahead, it's critical to have a solid understanding of this megabank before adding it to your portfolio. In The Motley Fool's premium research report on B of A, analysts Anand Chokkavelu, CFA, and Matt Koppenheffer, Financials bureau chief, lift the veil on the bank's operations, including detailing three reasons to buy and three reasons to sell. Click here now to claim your copy.

Top Investments For 2014: Solitron Devices Inc (SODI)

Solitron Devices, Inc., incorporated on March 12, 1987, designs, develops, manufactures and markets solid-state semiconductor components and related devices primarily for the military and aerospace markets. The Company manufactures a variety of bipolar and metal oxide semiconductor (MOS) power transistors, power and controls hybrids, junction and power MOS field effect transistors (Power MOSFETS), field effect transistors and other related products. It's products are custom made pursuant to contracts with customers whose end products are sold to the United States government. The Company�� semiconductor products can be classified as active electronic components. The Company�� active electronic components include bipolar transistors and MOS transistors.

The Company�� semiconductor products are used as components of military, commercial, and aerospace electronic equipment, such as ground and airborne radar systems, power distribution systems, missiles, missile control systems, and spacecraft. Its products have been used on the space shuttle and on the spacecraft sent to the moon, to Jupiter (on Galileo) and, to Mars (on Global Surveyor and Mars Sojourner).

Power Transistors

The Company manufactures a variety of power bipolar transistors for applications requiring currents in the range of 0.1 ampere to 300 ampere or voltages in the range of 30 volts to 1000 volts. It also manufactures power diodes under the same military specification. In addition, it manufactures power N-Channel and P-Channel MOSFET transistors and is expanding that line in accordance with customers��requirements.

Hybrids

The Company manufactures thick film hybrids, which generally contain discrete semiconductor chips, integrated circuits, chip capacitors and thick film or thin film resistors. The hybrids are of the high-power type and are custom manufactured for military and aerospace systems. Some of the Company�� hybrids include high power voltage regulators, p! ower amplifiers, power drivers, boosters and controllers. The Company manufactures both standard and custom hybrids.

Voltage Regulators

Voltage regulators provide the power required to activate electronic components such as the integrated circuits. These circuits are found in all electronic devices from radar and missile systems to smart phones.

Field Effect Transistors

The Company manufactures about 30 different types of junction and MOS field effect transistor chips. They are used to produce over 350 different field effect transistor types. The Company�� field effect transistors conform to standard Joint Electronic Device Engineering Council designated transistors, commonly referred to as standard 2N number types. It manufactures both standard and custom field effect transistors.

The Competes with IXYS Corporation, Motorola Inc., International Rectifier, Microsemi Corporation, M.S. Kennedy Corporation, Natel Engineering Company and Sensitron Semiconductor.

Advisors' Opinion:

• [By Geoff Gannon] on the amount of stock you can buy and the position size you like. For me, I try not to start buying a stock that I think will never make up 10% of my portfolio. If you don�� mind having 5% positions in your portfolio, your portfolio can obviously be twice as big as mine and you can still consider buying the same small stocks I do. In terms of specific stocks, it depends on the amount of float and the volume the stock trades in an average month. We are really getting into specifics here. And I may be boring people. But if you�� like to hear more about the minutiae of how you actually buy and sell tiny stocks like these, let me know, and I��l do an article on the subject.

  By the way, there is a hard and fast rule of thumb that it usually makes no sense to invest in a company with a market cap that is smaller than your portfolio. This is true for both fund and individual investors. Funds break it all the time. But, frankly, it is probably a waste of an analyst/fund manager�� time to even analyze such tiny positions relative to the size of the whole portfolio. Since even when we are discussing very small stocks we are still talking about millions and millions of dollars in market cap, this is hardly a concern for most individuals.

  So, for individual investors, actual inability to acquire enough shares of a company to meaningful influence their portfolio is rarely the problem. If you bid for a stock month after month ��you��l get your shares.

  The concern for individual investors is not whether buying enough shares is possible. The concern is how quickly and easily you can buy and sell. This is what we call ��iquidity.��/p>

  Instead of thinking about stocks as liquid or illiquid, you should think in terms of your portfolio and your liquidity needs. It doesn't make much sense to use what I'll call an "objective" (as in stock-oriented) approach to liquidity rather than a "subjective" (as in investor-oriented) approach to liquidity.

  <
• [By Geoff Gannon] strong>OPT-Sciences (OPST)

  Micropac

  Micropac is 76% owned by Heinz-Werner Hempel. He�� a German businessman. You can see the German company he founded here. He�� had control of Micropac for a long-time. I don�� have an exact number in front of me. But I would guess it�� been something like 25 years.

  ADDvantage

  ADDvantage Technologies is controlled by the Chymiak brothers. See the company�� April 4 press release explaining their decision to turn over the CEO position to an outsider. Regardless, the Chymiaks still control 47% of the company. Ken Chymiak is now chairman. And David Chymiak is still a director and now the company�� chief technology officer. Clearly, it�� still their company.

  By the way, the name ADDvantage Technologies has nothing to do with the Chymiaks. Today�� AEY really traces its roots to a private company called Tulsat. The Chymiak brothers acquired that company about 27 years ago. So, effectively, when you buy shares of AEY you are buying into a 27-year-old family-controlled company.

  That�� pretty typical in the world of net-nets.

  Solitron

  Solitron Devices is 29% owned by Shevach Saraf. He has been the CEO for 20 years. The post-bankruptcy Solitron has never known another CEO. Before the bankruptcy, Solitron was a much bigger, much different company. So even though we are not talking about the founder here ��and even though 70% of the company�� shares are not held by the CEO ��we��e still talking about a company where one person has a lot of control. Solitron only has three directors. Saraf is the chairman, CEO, president, CFO and treasurer. Neither of the other two directors joined the board within the last 15 years. So, we aren�� talking about a lot of tumult at the top.

  In fact, profitable net-nets seem to be especially common candidates for abandoning the responsibilities of a public company without actually getting taken private.

  OPT-Sciences

  This

• [By Geoff Gannon]

  Solitron (SODI) sells at 74% of NCAV, has decent z- and f-scores, a FCF margin of 5.3% and an ROA of 12%.
  
  Micropac (MPAD) sells at 83% of NCAV, has similar (slightly better) z- and f-scores, a FCF margin of 6%, but has ROA of 28%.
  
  ADDvantage (AEY) sells at 95% of NCAV, has similar (in the ballpark) scores and FCF and ROA of 23%.

Top Investments For 2014: Osiris Therapeutics Inc.(OSIR)

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. It operates in two business segments, Therapeutics and Biosurgery. The Therapeutics segment focuses on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. This segment focuses on developing biologic products for use in surgical procedures. The company?s lead biologic drug candidate is Prochymal, which is in phase 2 and 3 clinical trails for various indications, including acute graft versus host disease (GvHD), Crohn's disease, acute myocardial infarction, type 1 diabetes, pulmonary disease, and gastrointestinal injury resulting from radiation exposure. Its biologic drug candidates also include Chondrogen, a preparation of adult mesenchymal stem cells that is in phase 2 clinical trials for osteoarthritis and cartilage protection. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen in various countries except in the United States and Canada. It also has a partnership with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Advisors' Opinion:

• [By Maxx Chatsko]

  Additionally, stem cell therapies have remained elusive as the industry's ultimate Holy Grail. Osiris (NASDAQ: OSIR  ) received Canadian approval for the world's first stem cell drug, Prochymal, for children battling acute graft-versus-host disease, or GvHD, last year. The approval meant more symbolically than to the bottom line, but it definitely put the potential of stem cells front and center for investors.

Hot Cheap Companies To Invest In Right Now: Aerosonic Corporation(AIM)

Aerosonic Corporation, together with its subsidiaries, engages in the design, manufacture, and sale of aircraft instruments worldwide. It offers mechanical and digital altimeters, airspeed indicators, rate of climb indicators, microprocessor controlled air data test sets, and other flight instruments. The company also produces mechanical and electro-mechanical cockpit instruments, angle of attack stall warning systems, digital cockpit instruments, integrated flight display systems, aircraft sensors and monitoring systems, and integrated multifunction probes, such as integrated air data sensors. It markets its products to manufacturers of corporate and private jets, contractors of military jets, the United States government, and private aircraft owners. The company sells its products directly through its sales personnel, as well as through distributors and commissioned sales representatives who resell to aircraft operators. Aerosonic Corporation was founded in 1953 and is b ased in Clearwater, Florida.

Advisors' Opinion:

• [By Katia Dmitrieva]

  Aimia (AIM) Inc.�� decision to move its Aeroplan reward-partnership to Toronto-Dominion (TD) Bank is a blow to Canadian Imperial Bank of Commerce, which stands to lose customers and as much as C$3 billion ($2.9 billion) in credit-card balances.

Top Investments For 2014: Zoom Technologies Inc (ZOOM)

Zoom Technologies, Inc. (Zoom), incorporated on February 29, 2002, is engaged in design, production, marketing, sales, and support of broadband and dial-up modems, voice over Internet Protocol or (VoIP) products and services, Bluetooth wireless products, and other communication-related products. The Company through its wholly owned holding-company subsidiary, Gold Lion Holding Limited (Gold Lion) is the owner of 100% of Profit Harvest Corporation Ltd. (Profit Harvest) and through Gold Lion's wholly owned subsidiary, Jiangsu Leimone Electronics Co., Ltd. (Jiangsu Leimone) is the owner of 80% of Tianjin Tong Guang Group Digital Communication Co., Ltd. (TCB Digital). The Company through its subsidiaries is engaged in manufacturing, research and development, and sales of electronic and telecommunication products for the latest generation mobile phones, wireless communication circuitry, and related software products. On January 4, 2011, the Company acquired 100% ownership of Celestial Digital Entertainment, Ltd., (CDE). During the year ended December 31, 2011, the Company acquired 55% of Portables.

TCB Digital is engaged in electronic and telecommunication product design, development, and manufacturing for original equipment manufacturers (OEM) customers and for its own products under the brand name of Leimone. The Company offers electronic manufacturing service (EMS) to both domestic and global customers including Samsung, Beijing Tianyu Langtong, CECT, Danahar and Spreadtrum. Its primary products include mobile phones, wireless telecommunication modules, digital cameras, cable television (TV) set-top boxes and global positioning system ( GPS) equipment.

The Company has developed mobile phones and Smartphones based on both of the main network technologies: Global System for Mobile Communications (GSM), and Code Division Multiple Access (CDMA), and beginning in 2010 also 3G CDMA2000 capable products. As of December 31, 2011, the Company markets its mobile phone products through di! stributors in China and also supplies GSM, CDMA and 3G CDMA2000 mobile phones to customers, including one of China's main mobile operators, China Telecom. The Company through its Portables subsidiary operates a wholesale distributor business for T-Mobile products and services in the United States. The Company also has the right to sell branded mobile handsets including those carrying the Zoom brand name and related peripherals in the retail stores managed by Portables under the agreement with T-Mobile.

The Company competes with Bird Ningbo Co., Ltd, Haier Telecom Co. Ltd., Konka Group Co., Ltd, Lenovo Group Limited, TCL Communication Technology Holdings Limited, LG Electronics Ltd., Motorola Inc., Nokia Corporation, Samsung Electronics Co., Ltd., and Sony Ericsson Mobile Communications (China) Co., Ltd.

Advisors' Opinion:

• [By Lauren Pollock]

  Shares of Zoom Technologies Inc.(ZOOM) soared� 37% to $5.90 after the Chinese mobile and telecommunications investor inked an all-stock deal to acquire an online business travel provider.

Top Investments For 2014: Network Exploration Ltd (NET)

Network Exploration Ltd. is an exploration and development-stage company. The Company�� principal business activities include the exploration of minerals in its mineral properties. It focuses on base and precious metal properties in North and South America. Its activities include the process of exploring its mineral properties, reviewing and subsequently acquiring mineral properties and conducting exploration programs to determine whether these properties contain ore reserves that are recoverable. The Picha copper-silver project is located within the Tertiary Volcanic Arc of Southern Peru. The Pistala project is located east of the NW-SE trending Incapquio fault system in the Department of Tacna, Southern Peru. The Company is in the business of mineral exploration in Canada, Chile and Peru. Network Exploration Chile Limitada is its wholly owned subsidiary. Advisors' Opinion:

• [By Holly LaFon]

  The MSCI World ex U.S. Small Cap Index (Net) is a free float-adjusted market capitalization index that is designed to measure global developed market equity performance, excluding the U.S. The MSCI Small Cap Indices target 40% of the eligible Small Cap universe within each industry group, within each country. MSCI defines the Small Cap universe as all listed securities that have a market capitalization in the range of USD200-1,500 million. This benchmark calculates reinvested dividends net of withholding taxes using Luxembourg tax rates. This index is unmanaged and investors cannot invest directly in this index.

• [By Holly LaFon]

  The MSCI World Index (Net) is a free float-adjusted market capitalization weighted index that is designed to measure the global equity market performance of developed markets. This benchmark calculates reinvested dividends net of withholding taxes using Luxembourg tax rates. This index is unmanaged and investors cannot invest directly in this index.

• [By Patience Investing Inc.]

  Sl. No Portfolio Style Description Annualized Performance (Net) Since Inception or Longest Period Primary Benchmark Relative Performance 1 Emerging Markets Equity Stocks of companies in emerging countries 8.35% 6.29% 2.06% 2 European Equity Stocks of companies in European countries 8.48 6.20 2.28 3 Global Balanced Mix of global stocks and bonds 7.60 6.37 1.23 4 Global Equity Stocks of U.S. & non-U.S. companies 12.40 9.24 3.16 5 Global Mid Cap Equity Stocks of mid-sized U.S. and Non-U.S. companies 3.85 6.14 -2.29 6 Global Small Cap Equity Stocks of smaller U.S. and Non-U.S. companies 6.00 6.26 -0.26 7 International Equity Stocks of non-U.S. companies 9.57 4.56 5.01 8 International Mid Cap Equity Stocks of mid-sized non-U.S. companies 5.61 5.93 -0.32 9 International Small Cap Equity Stocks of smaller non-U.S. companies 7.84 5.87 1.97 10 U.S. Mid Cap Value Equity Stocks of mid-sized U.S. companies 3.40 7.05 -3.65 11 U.S. Small Cap Value Equity Stocks of smaller U.S. companies 3.07 4.84 -1.77 12 U.S. Value Equity Stocks of U.S. companies 6.91 7.81 -0.90 Source: Compiled from http://www.brandes.com/Inv/Pages/Performance.aspx

• [By Jason Rivera]

  Assets:Book Value:Reproduction Value:Current AssetsCash And Cash Equivalents506506Accounts Receivable (Net)3,6193,076Inventories10,0006,000Deferred Income Taxes919460Prepaid Expenses799400Total Current Assets15,8439,986PP&E Net2,4151,449Equity and Other Investments4,5763,432Intangible Assets3,1391,570Deferred Income Taxes991496Total Assets26,96417,387
  Number of shares is 7,383.

Top Investments For 2014: Trovagene Inc (TROV)

TrovaGene, Inc. (TrovaGene), incorporated on April 26, 2002, is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�� urine-based test addresses market needs, such as women�� healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform.

On January 18, 2011, the Company entered into an asset purchase agreement pursuant to which the Company acquired a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker. On February 8, 2011, the Company entered into a sublicense agreement with MLL Munchner Leukamielabor (MLL). In July, 2011, the Company entered into a sublicense agreement with Fairview Health Services (Fairview) for NPM1 patent rights.

In October 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia. On December 12, 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to hairy cell leukemia biomarkers. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).

Advisors' Opinion:

• [By Roberto Pedone]

  TrovaGene (TROV) is a development stage molecular diagnostic company focused on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. This stock closed up 6% to $10.02 in Friday's trading session.

  Friday's Volume: 712,000
  
  Three-Month Average Volume: 183,106
  
  Volume % Change: 294%

  From a technical perspective, TROV ripped higher here into all-time high territory with heavy upside volume. This stock has been uptrending strong for the last month and change, with shares soaring higher from its low of $5.75 to its new all-time high of $10.20. During that move, shares of TROV have been making mostly higher lows and higher highs, which is bullish technical price action. That move has also been accompanied by bullish upside volume flows.

  Traders should now look for long-biased trades in TROV as long as it's trending above its recent breakout level of $8.83, and then once it sustains a move or close above its all-time high of $10.20 with volume that hits near or above 183,106 shares. If we get that move soon, then TROV will set up to enter new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $13 to $15.

• [By Daniel Lauchheimer]

  In the past few weeks, I wrote two articles about TrovaGene (TROV) -- one detailing the history of the DNA market generally and the molecular diagnostics -- and TROV's place therein -- market specifically, and the second detailing the company's internal valuation. In this article, I will value TROV on an external, relative basis. Specifically, I will compare TROV to another molecular diagnostics company, Exact Sciences (EXAS), and try to show that while the market seems to have given EXAS a fair shake, it has not done the same for TROV. I will prove this argument by looking at both companies' addressable markets, and their respective progress at bringing the products to market. However, before we take this deep dive into both companies, I will take a moment to review each of the companies' products, so we have a strong background before turning to the deeper analysis.

• [By David Goodboy]

  Fortunately, diagnostic issues may soon be a thing of the past. Several publicly traded companies are currently making great strides in the field of medical diagnostics, and my favorite company right now in that arena is TrovaGene (Nasdaq: TROV).